Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complications associated with CDDP intraperitoneal chemotherapy

S Adachi1, T Noda, K Ito

  • 1Department of Obstetrics and Gynecology, Saiseikai Tondabayashi Hospital, Osaka, Japan.

Asia-Oceania Journal of Obstetrics and Gynaecology
|March 1, 1994
PubMed
Summary

Intraperitoneal chemotherapy using cisplatin (CDDP-ip) can treat abdominal tumors. This study evaluated complications from temporary and implantable catheters used for CDDP-ip delivery, finding lower complication rates with implantable ports.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia.

American journal of reproductive immunology (New York, N.Y. : 1989)·1999
Same author

A phase I study of cisplatin i.p. and carboplatin i.v. with G-CSF in patients with ovarian cancer.

Oncology reports·1999
Same author

Enhancement by stem cell factor of interleukin-2 (IL-2)-induced DNA synthesis in human decidual CD16- CD56bright natural killer cells mediated by increased expression of the IL-2 receptor alpha chain.

Journal of reproductive immunology·1998
Same author

Functional expression on human trophoblasts of interleukin 4 and interleukin 7 receptor complexes with a common gamma chain.

Biochemical and biophysical research communications·1997
Same author

Interleukin 4 (IL-4) blocks the IL-2-induced increased in natural killer activity and DNA synthesis of decidual CD16-CD56bright NK cells by inhibiting expression of the IL-2 receptor alpha, beta, and gamma.

Cellular immunology·1996
Same author

Expression of the interleukin-2 receptor gamma chain on cord blood mononuclear cells.

Blood·1996

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Devices

Background:

  • Intraperitoneal chemotherapy with cisplatin (CDDP-ip) is effective for intraperitoneal tumors, including ovarian cancer.
  • CDDP-ip administration requires catheter placement, often during laparotomy.
  • Complications associated with intraperitoneal (ip) catheter use need thorough investigation.

Purpose of the Study:

  • To investigate and compare the complication rates of temporary catheters versus implantable port and catheter systems for intraperitoneal chemotherapy delivery.

Main Methods:

  • Retrospective analysis of 84 patients receiving ip chemotherapy.
  • Categorization of patients into two groups: temporary catheters (n=39) and implantable port systems (n=45).
  • Documentation and comparison of catheter-related complications between the two groups.

Related Experiment Videos

Main Results:

  • Temporary catheters were associated with a 27% complication rate, including infection (8%), inflow obstruction (3%), leakage (5%), extrusion (8%), and severe pain (3%).
  • Implantable port systems had a 22% complication rate, including inflow obstruction (9%), infection (2%), leakage (4%), and extrusion (7%).
  • No serious complications were reported at the study institutions, with observed rates appearing lower than in other centers.

Conclusions:

  • Both temporary and implantable port catheter systems are associated with manageable complications for ip chemotherapy.
  • Implantable port systems may offer a lower complication profile compared to temporary catheters for intraperitoneal chemotherapy delivery.
  • Further research is warranted to optimize ip chemotherapy delivery and minimize associated risks.